Research programme: stimulator of interferon genes agonists - iTeos Therapeutics
Alternative Names: STING agonist - iTeos TherapeuticsLatest Information Update: 28 Feb 2022
At a glance
- Originator iTeos Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in Belgium
- 15 Jan 2018 Stimulator of interferon genes agonists programme is available for licensing as of 15 Jan 2018. http://www.iteostherapeutics.com/partnerships/objectives (iTeos Therapeutics website, January 2018)
- 15 Jan 2018 Early research in Cancer in Belgium before January 2018 (iTeos Therapeutics pipeline, January 2018)